The landscape for large pharmaceutical companies has changed radically in the last year.

Their model used to be that they would spend huge sums on R&D and then push blockbuster drugs into the market.

These drugs would often be worth billions of dollars in revenue each year, and were protected from competition by patents.

But, a number of those patents are expiring, and generic manufacturers are moving into the drug market with cheaper versions of the products.

The success of this trend is fueled by government desires to keep down health care costs.

Early this year, Pfizer (NYSE: PFE) cut 10,000 jobs. The company said that rising competition from generics would pressure its operating profits for the next several years.

Wall Street analysts pegged the drop in Pfizer's annual revenue due to generic competition at as much as $14 billion a year. The biggest drug in Pfizer's stable about to go "off patent" is its hugely successful cholesterol drug Lipitor.

URCH Publishing recently put out a report that forecast $100 billion in sales of big pharma drugs will be at risk between 2007 and 2011. Bristol-Myers Squibb (NYSE: BMY), Takeda, AstraZeneca and Eli Lilly (NYSE: LLY) have 40% of their revenue competing with new generics and for Merck (NYSE: MRK) and Pfizer the figure is closer to 50%.

It will be a windfall for generic companies, which may be able to add $20 billion in revenue over the next five years.

Investors have known for some time that this day would come. The patent expiration dates for key drugs are readily available. And, the growing concern shows in the stock prices. Over the last five year, shares in Pfizer are down 40%. Shares in Bristol-Myers are down 46% and shares in Merck are off 28%.

Perhaps the best example of how investors have been able to benefit from the trend toward generics is the public company Teva Pharmaceutical (Nasdaq: TEVA).

Shares in the Israeli company are up over 150% during the last five years. One of its rivals, Barr Pharmaceuticals (NYSE: BRL), has seen its stock up 50% over that same period.

The pressure on drug prices is mounting as both the state and federal governments try to hold down medical costs. Eleven governors recently banded together in an attempt to drive down the cost of insulin.

Consumers, the government, and private insurers spend $3.3 billion on the diabetes drug each year. Analysts say that a generic version could push those costs down by 25%.

The remaining question for big pharma shareholders is whether the large R&D operations at these companies can create patented drugs to replace those that are now the target of the generics companies.

With falling revenue opportunities the money for R&D may not be so plentiful, and that is a very big problem.

Looking to cook up a market-stomping stock portfolio? Check out our FREE report "7 Ingredients to Market Beating Stocks" and get started right now!

Related Articles
  1. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  2. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  3. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  4. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  7. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  8. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  9. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  10. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!